Compare Agilent Technologies Inc (A) vs Barclays PLC (BCS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Barclays PLC — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Barclays PLC trades at $27.87 (market cap $94.10B). The key difference: Barclays PLC is far larger — about 2.2× Agilent Technologies Inc's market cap, and Barclays PLC pays the higher dividend (2.18%). Which is the better fit depends on your goals.
| A | BCS | |
|---|---|---|
Market Cap | $42.00B | $94.10B |
Sector | Health | Financials |
52-Week High | $157.20 | $28.56 |
52-Week Low | $110.24 | $19.36 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Barclays PLC (BCS) trades at $27.93, down 0.89% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.90 exceeding the $0.89 estimate. Revenue grew to $29.14 billion in 2025, with a net income margin of 25.51%. Analyst consensus is 68% buy, though recent news highlights a securities class action investigation.
The outlook for BCS is positive given earnings momentum and a low P/E of 10.73, but risks include the legal investigation and rising costs noted in Q2 2026. Investment opportunity lies in valuation discount and dividend yield, while sentiment is mixed due to near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →
